The U.S. Food and Drug Administration (FDA) has approved Guardant Health Inc.'s Guardant360 Liquid CDx test, significantly expanding its capabilities in blood-based genomic profiling for patients with advanced cancer. This updated test is now recognized as the largest FDA-approved liquid biopsy panel, evaluating a genomic footprint that is 100 times wider than its predecessor, the Guardant360 CDx. The new test integrates both genomic and epigenomic insights from a single blood sample, providing clinicians with more comprehensive data to inform treatment decisions. Powered by Guardant's Smart Platform, an AI-enabled multiomic technology, the test enhances the sensitivity of circulating tumor DNA detection. Results can be delivered in as little as seven days, making it a valuable tool for treatment selection regardless of tissue availability or therapy line. Additionally, the Guardant360 Liquid CDx is the first liquid biopsy capable of identifying both genotype and key phenotype information simultaneously. Following the FDA's approval, Guardant Health's stock rose by 8.81%, reflecting positive market sentiment.